Subtitle: Study Shows KZ-36 Peptide Significantly Reduces Proteinuria and Improves Renal Function in Rat Masugi Nephritis Model

A 2004 study published in the Journal of Chinese Medicinal Materials demonstrates that KZ-36, a small-molecule peptide extracted from bovine spleen, exerts potent therapeutic effects on Masugi nephritis in rats by suppressing autoimmune responses, reducing proteinuria, and preserving renal architecture—offering a promising approach for immune-mediated kidney disease.

Polypeptide mixtures derived from animal spleens have long been recognized for their immunomodulatory potential and are sometimes used as adjunctive therapy in oncology. However, their clinical application has been significantly limited by compositional complexity and lack of pharmacological specificity. KZ-36, a small-molecule peptide extracted from bovine spleen through systematic isolation and screening, represents a significant advancement—a defined, low-molecular-weight peptide with potent immunosuppressive activity identified through rigorous pharmacological screening.

The Study: Investigating KZ-36 in Autoimmune Nephritis

Objective: To observe the therapeutic effect of bovine spleen peptide KZ-36 on Masugi nephritis in rats—a classic animal model of autoimmune glomerulonephritis induced by nephrotoxic serum.

Methods:

Key Research Findings

1. Reduction in 24-Hour Urinary Protein Excretion

Urinary protein excretion is a cardinal marker of glomerular injury and a key indicator of nephritis severity. As shown in Table 1, the model group exhibited a dramatic increase in 24-hour urinary protein from 1.5±0.3 mg (pre-modeling) to 22.9±18.6 mg one week post-modeling (P<0.01), confirming successful establishment of Masugi nephritis.

*P<0.05, *P<0.01 vs. Model Group

In the KZ-36 treated group, 24-hour urinary protein excretion at both the first and second weeks after administration was significantly lower than in the model group (P<0.05 and P<0.01, respectively). Notably, while hydrocortisone showed stronger immediate effect at week 1, KZ-36 demonstrated continued improvement through week 2 with no evidence of rebound.

2. Improvement in Serum Creatinine Levels

Serum creatinine (Cr) is a critical indicator of renal function. Elevated Cr reflects impaired glomerular filtration.

The model group and hydrocortisone group both exhibited significantly elevated serum Cr levels compared to normal controls (P<0.01), indicating that nephrotoxic serum induced nephritis accompanied by impaired renal function. In contrast, the KZ-36 group showed serum Cr levels (86±13 μmol/L) remarkably close to normal controls and significantly reduced compared to the model group (P<0.01), demonstrating KZ-36′s beneficial effect on preserving renal function.

3. Effects on Kidney and Spleen Indices

Organ indices (organ weight relative to body weight) provide insight into pathological organ changes. As shown in Table 2, the model group exhibited significant organ enlargement:

*P<0.05, *P<0.01 vs. Normal

The model group demonstrated significant kidney enlargement (P<0.05) and even more pronounced splenomegaly (P<0.01). The marked splenomegaly indirectly proves the involvement of hyperimmune factors in the pathological process of this nephritis. While KZ-36 showed no significant effect on kidney enlargement, it significantly reduced the spleen index compared to the model group, suggesting that KZ-36 exerts its therapeutic effects by suppressing the hyperimmune response driving the disease.

4. Renal Pathological Findings

Histopathological examination revealed characteristic glomerulonephritis changes in the model group:

• Slight fibrinous exudate in Bowman’s capsule space
• Proliferation of parietal epithelial cells with some forming crescents
• Glomerular capillary dilation and congestion
• Mild hydropic degeneration in proximal convoluted tubule epithelial cells
• Occasional casts in distal convoluted tubules and collecting ducts

These findings are fully consistent with the pathological features of glomerulonephritis. In the hydrocortisone group, microscopic findings were essentially similar to normal controls. In the KZ-36 group, only occasional mild hydropic degeneration in proximal convoluted tubule epithelium was observed, and glomeruli appeared generally similar to the normal group—demonstrating impressive renal protection.

Discussion: The Therapeutic Potential of Targeted Small-Molecule Peptides

Why KZ-36 Represents an Advancement:

Research has established that peptide extracts derived from immune organs possess potent immunomodulatory functions, as seen with thymosin and spleen transfer factor. However, traditional spleen-derived preparations contain complex mixtures of numerous peptide monomers, whose functions may exhibit both synergistic and antagonistic effects. Therefore, isolating individual components, followed by systematic screening and identification, holds significant pharmacological importance.

Key Characteristics of KZ-36:

Connecting Immunosuppression to Therapeutic Effect:

The Masugi nephritis model, also known as nephrotoxic serum nephritis, is induced by direct injection of heterologous anti-glomerular basement membrane (GBM) antibodies. Pathogenetically, it is classified as an autoimmune disease. The significant splenomegaly observed in nephritic rats indirectly confirms the involvement of hyperimmune factors in the disease process. KZ-36′s ability to reduce splenomegaly while simultaneously decreasing proteinuria, normalizing serum creatinine, and preserving renal architecture strongly suggests that its therapeutic mechanism involves suppression of the pathological autoimmune response.

Conclusions and Implications

Based on comprehensive experimental observations, the authors conclude:

1. KZ-36, a bovine spleen-derived small-molecule peptide, demonstrates significant therapeutic effects on Masugi nephritis in rats.
2. Key therapeutic outcomes include:
   • Significant reduction in 24-hour urinary protein excretion
   • Normalization of serum creatinine levels
   • Alleviation of splenomegaly
   • Preservation of normal renal architecture with only minimal pathological changes
3. Proposed mechanism: KZ-36 likely exerts its effects through immunosuppression, dampening the autoimmune response that drives glomerular injury in this model.
4. Pharmacological significance: This study validates the approach of isolating and screening individual peptide components from complex organ extracts to identify molecules with specific, potent therapeutic activities.

References

[1] Borghardt J, et al. Effects of a spleen peptide preparation as supportive therapy in inoperable head and neck cancer patients. Arzneimittelforschung, 2000, 50(2): 178.

[2] Chen Xiaobing, et al. Clinical study of Polyerga combined with chemotherapy in the treatment of advanced lung cancer. Chinese Journal of Clinical Oncology, 1999, 26(7): 532.

[3] Xu Shuyun, Editor-in-Chief. Methodology of Pharmacological Experiments (3rd Edition). Beijing: People’s Medical Publishing House, 2002: 1227-1228.

[4] Sha Ying, et al. A new immunomodulator – Thymosin α1. Chinese Pharmaceuticals, 2001, 10(11): 80.

[5] Zhang Xinwei, et al. The role of oral freeze-dried porcine spleen transfer factor in the treatment of malignant tumors and its effect on immune function. Chinese Journal of Experimental and Clinical Immunology, 1995, 7(5): 34.